In a report released yesterday, Brian Abrahams from RBC Capital maintained a Hold rating on ATAI Life Sciences (ATAI – Research Report), with a price target of $12.00. The company's shares closed last Thursday at $6.60, equals to its 52-week low of $6.60. According to TipRanks.com, Abrahams is a 2-star analyst with an average return of 0.2% and a 46.6% success rate. Abrahams covers the Healthcare sector, focusing on stocks such as Intra-Cellular Therapies, Karyopharm Therapeutics, and Enanta Pharmaceuticals. The word on The Street in general, suggests a Strong Buy analyst consensus rating for ATAI Life Sciences with a $26.57 average price target.
https://www.tipranks.com/news/blurbs/atai-life-sciences-atai-receives-a-hold-from-rbc-capital?utm_source=advfn.com&utm_medium=referral
ATAI Life Sciences NV (NASDAQ:ATAI)
Historical Stock Chart
From Apr 2022 to May 2022 Click Here for more ATAI Life Sciences NV Charts.
ATAI Life Sciences NV (NASDAQ:ATAI)
Historical Stock Chart
From May 2021 to May 2022 Click Here for more ATAI Life Sciences NV Charts.